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SUMMARY: Kılıç-Yıldırım G, Durmuş-Aydoğdu S, Ceylaner S, Sass JO. Beta-
ketothiolase deficiency: An unusual cause of recurrent ketoacidosis. Turk J 
Pediatr 2017; 59: 471-474.
Beta-ketothiolase deficiency (mitochondrial acetoacetyl-CoA thiolase, MAT 
or T2 deficiency) is a rare autosomal recessive disorder of isoleucine and 
ketone body metabolism due to acetyl-CoA acetyltransferase-1 (ACAT1) gene 
mutations. The disease is characterized by recurrent episodes of ketoasidosis 
which starts with vomiting and followed by dehydration and tachypnea. Here, 
we present a patient who was admitted to the hospital with severe acidosis 
and dehydration because of vomiting induced by protein rich nutrient and was 
diagnosed with MAT deficiency. 3-hydroxy-butyric acid, acetoacetic acid and 
3-hydroxy-iso-valeric acid levels were significantly increased and tiglyglycine 
as trace amount in the urine organic acid analysis of the patient. Genetic 
analysis for ACAT-1 showed compound heterozygosity for the mutations 
c.949G>A (p.D317N) and c.951C>T (p.D317D), which both are known to 
cause exon 10 skipping and to be pathogenic missense mutations. 
Key words: recurrent ketoacidotic episodes, keton bodies, tiglyglycine, isoleucine 
metabolism.
Beta-ketothiolase deficiency (mitochondrial 
acetoacetyl-CoA thiolase MAT or T2 deficiency) 
is a rare autosomal recessive disorder of 
isoleucine and ketone body metabolism. Succinyl-
CoA: 3-oxoacyl-CoA transferase (SCOT) and 
MAT are the main ketolytic enzymes.1,2 This 
disorder was first described in 1971 by Daum 
et al.3 and more than 100 patients are known.2,3 
The responsible gene ACAT1 is located on 
chromosome 11q22.3-23.1.4 MAT deficiency 
is not found reliable in newborn screening.5,6 
The incidence was reported as 1 in 232,000 
taking into account missed cases by newborn 
screening in Minnesota, USA.6
MAT deficiency is characterized by recurrent 
attacks of ketoacidosis. Neonatal onset is rare. 
Patients are generally asymptomatic between 
episodes. Dehydration, hyperventilation, 
lethargy, coma and death may occur during 
the episodes. 
Here, we present a patient with MAT deficiency. 
Organic acid analysis is diagnostic for this 
disorder. However, in the present case, urinary 
organic acid analysis has shown only subtle 
findings even during severe ketoacidotic 
episode.
Case Report
A twenty-two-month-old boy was admitted to 
the hospital with severe metabolic acidosis and 
dehydration because of vomiting induced by 
protein rich nutrient. He had three episodes of 
severe acidosis and required hospital admission 
for parenteral alkaline therapy before. He was 
the first child of non-consanguineous parents. 
He had normal growth and development. 
In physical examination he was lethargic, 
dehydrated, tachypneic and had acetone 
odor. Clinical test showed, blood glocose 65 
mg/dl, sodium 139 mEq/L, potasium 3.85 
mEq/L, chlorine 104 mEq/L, BUN 37.2 mg/
dl, creatinine 0.52 mg/dl, uric acid 13.9 mg/
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dl, blood ammonia 108 μg/dl, lactate 15 mg/
dl and pyruvate 0.9 mg/dl. Venous blood gas 
analysis showed a pH of 7.26, PCO2 17.9 
mmHg, bicarbonate 7.8 mmol/L, base excess 
-18.2 mmol/L. Urine ketone was 4(+). He 
was treated with intravenous alkaline therapy, 
L-carnitine, biotin and vitamin B12 due to 
suspicion of organic acidemia. Urinary ketones 
became negative and the blood gas data was 
normal on the second day and then oral Shohl 
solution was started. Branched chain amino 
acid levels in urine were elevated on one sided 
paper chromatography. Blood acylcarnitine 
analysis was normal. 3-hydroxy-butyric acid, 
acetoacetic acid and 3-hydroxy-iso-valeric 
acid levels were significantly increased and 
tiglyglycine as trace amount in the urine organic 
acid analysis. The result of the enzyme assays 
in lymphoblast homogenates (obtained from 
lymphocytes immortalized with Epstein Barr 
virus) provided no indication for the ketolysis 
defect SCOT deficiency (SCOT activity: 14.1 
nmol acetoacetyl-CoA min-1 mg-1 protein, which 
closely resembles activities of the negative 
controls, while no detectable activity was found 
in a SCOT deficient positive control), but the 
data did not exclude methylacetoacetyl-CoA 
thiolase (MAT; ‘beta-ketothiolase’) deficiency, 
which would be detected in a more reliable 
manner in cultivated fibroblasts, which were 
not available. Because of the small amount 
of tiglyglycine in the urinary organic acids, 
we then approached a diagnostic work-up 
towards MAT deficiency on the gene level. 
Mutation analysis of the ACAT1 gene showed 
heterozygosity for the mutations c.949G>A 
(p.D317N) and c.951C>T (p.D317D). After 
the diagnosis of T2 deficiency, the patient was 
treated with oral Shohl solution, L–carnitine 
and low isoleucine diet. There was no new 
episode under this treatment during a follow-
up period of 32 months.
Written informed consent was obtained from 
the parents of the patient for publication of 
this case report.
Discussion
Most patients with T2 deficiency present 
during the first two years of life, but some of 
them remain asymptomatic into adulthood.7 
Episodes of acute illness are induced most 
commonly by infections and other cause of 
catabolism. They can also be induced by high 
protein intake. During episodes of acute illness, 
patients often require admission to hospital and 
parenteral alkaline fluid therapy. The frequency 
of episodes diminishes by age. Intellectual 
development is generally normal, but some have 
mental retardation, speech problems, ataxia, 
chorea or dystonia with abnormalities in the 
basal ganglia on MRI.8-11 A few patients have 
seizures, especially during acute episodes.12 
Severe central hypotonia and congestive cardiac 
myopathy were also reported.9,13,14
The case was at twenty-two months of age at 
first presentation. It seems that high protein 
intake was the triggering factor for the last 
episode in the patient. He had three episodes 
of severe acidosis and required admission to 
the hospital for parenteral alkaline fluid therapy. 
He had normal growth and development and 
normal cardiac functions. 
In most patients, blood glucose, lactate and 
ammonia concentrations are normal, but there 
may be hypoglycemia or hyperglycemia.15,16 
Amino acid concentrations are usually normal 
but sometimes branched chain amino acid levels 
are elevated, as in our patient.
We suspected ketolysis defect or other 
ketoacidotic states because of recurrent 
ketoacidotic episodes history, metabolic 
acidosis, acetone odor and highly elevated keton 
bodies in urine in our patient on admission. 
3-hydroxy-butyric acid, acetoacetic acid and 
3-hydroxy-iso-valeric acid levels were increased 
significantly and tiglyglycine was detected in 
trace amounts in the urine organic acid analysis. 
Clinical findings are similar in deficiencies of 
beta-ketothiolase and succinyl-CoA 3-oxoacid 
CoA transferase (SCOT), another ketolytic 
enzyme. In the acute decompensation, the 
latter usually presents with the urinary organic 
acid pattern with high concentrations of 
3-hydroxy-n-butyrate and acetoacetate only. 
In addition, 2-methyl-3-hydroxybutyrate, 
2-methylacetoacetate and tiglicylate are typically 
found in MAT deficiency.
Because organic acid findings were initially 
not considered typical for MAT deficiency we 
excluded SCOT deficiency in our patient first 
and only latter approached genetic analysis for 
MAT deficiency because of a trace amount of 
tiglyglycine in the urine organic acid analysis. 
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Blood acylcarnitine analysis generally shows 
increased 2-metyl-3-hydroxybutrylcarnitine 
(C5-OH acylcarnitine) and tiglylcarnitine (C5:1 
acylcarnitine) in MAT deficiency, although this 
is not a consistent finding.17 Acylcarnitine 
levels were within normal limits in our patient 
during the ketoacidotic episode.
Mutation analysis for ACAT-1 showed compound 
heterozygosity for the mutations c.949G>A 
(p.D317N) and c.951C>T (p.D317D). While 
the latter mutation may be mistaken as a silent 
mutation, both sequence variants have been 
demonstrated to cause exon 10 skipping and to 
be pathogenic missense mutations.18,19 DNA of 
the parents has also been studied: The patient’s 
mother was heterozygous for c.949G>A 
(p.D317N), and his father was heterozygous 
for c.951C>T (p.D317D) mutation.
The absence of detectable tiglyglycine suggests 
a biochemically mild phenotype, with some 
residual activity2, which –in this case- may be 
explained by the production of some normally 
spliced mRNA.18 
During acute attacks in MAT deficiency, 
immediate correction of hypoglycemia is 
needed, followed by constant high-rate glucose 
infusion.12 Alkalinisation should be considered 
in a very pronounced acidosis as should the 
administration of L-carnitine if its blood 
level is low. For prevention of metabolic 
decompensations fasting must be avoided. An 
additional bedtime snack and mild protein 
restriction should be considered and potential 
L-carnitine deficiency compensated.12
MAT deficiency is a life-threatening disease 
and should be considered in the differential 
diagnosis of ketoacidosis. Early diagnosis and 
management can prevent recurrent episodes. 
Patients with MAT deficiency who have a 
mild mutation with some residual activity may 
show subtle abnormality in urine organic acid 
analysis and normal acylcarnitine profiles even 
during acute ketoacidotic episodes. 
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